Drugs For Neglected Diseases Initiative, North America
Meets Standards
Standards For Charity Accountability
Governance
-
Board Oversight
-
Board Size
-
Board Meetings
-
Board Compensation
-
Conflict of Interest
Measuring Effectiveness
-
Effectiveness Policy
-
Effectiveness Report
Finances
-
Program Expenses
-
Fundraising Expenses
-
Accumulating Funds
-
Audit Report
-
Detailed Expense Breakdown
-
Accurate Expense Reporting
-
Budget Plan
Fundraising & Info
-
Truthful Materials
-
Annual Report
-
Website Disclosures
-
Donor Privacy
-
Cause Marketing Disclosures
-
Cause Marketing Disclosures
Drugs For Neglected Diseases Initiative, North America meets the 20 Standards for Charity Accountability.
Stated Purpose:
The Drugs for Neglected Diseases initiative (DNDi) is an international not-for-profit research and development (R&D) organization created in 2003 by Doctors Without Borders/Médecins Sans Frontières (MSF) and five public research institutions from India, Brazil, Kenya, Malaysia, France. DNDi was a response to the frustration by MSF field staff of being faced with medicines that were ineffective, highly toxic, unavailable, or had never been developed.
In 2008, DNDi opened its office in New York City to serve as the headquarters for DNDi North America. The office works to strengthen and expand DNDi’s scientific, policy and advocacy, partner development, communications, and resource mobilization efforts.
Year, State Incorporated:
2007, DE
Driven first and foremost by patient needs, DNDi takes an open, collaborative approach to R&D, bringing together the public, private, academic, and philanthropic sectors to carry out highly focused drug discovery and development. DNDi currently manages more than 20 R&D projects, including 20 potential new chemical entities across its R&D initiatives, which include units focused on: Neglected Tropical Diseases (sleeping sickness, leishmaniasis, Chagas disease, mycetoma, and filarial infections) and HIV and hepatitis C virus (HCV). In 2016, DNDi joined with the World Health Organization (WHO) to create and incubate the Global Antibiotic Research and Development Partnership (GARDP) to respond to the global challenge of antimicrobial resistance. GARDP is now an independent organization with close ties to both DNDi and WHO.
DNDi’s primary objective is to deliver 16 to 18 new treatments by 2023. Secondary objectives include utilizing and strengthening clinical research capacities in neglected disease-endemic countries by training scientists and health workers, equipping hospitals, labs and clinics, and carrying out clinical trials that meet international standards; and influencing the global health R&D landscape by advocating for sound, enabling public policies to ensure patients’ needs are prioritized over profits.
In its first 15 years, DNDi has developed and delivered eight field-adapted, affordable, and non-patented treatments for five deadly diseases and built the most robust research pipeline ever for some of the world’s most neglected diseases.
For the year ended December 31, 2022, Drugs For Neglected Diseases Initiative, North America's program expenses were:
| Grant – Research & Development | $1,777,205 |
| Salaries and Benefits | $774,846 |
| Communications and Education | $124,821 |
| Professional Fees | $42,077 |
| Transportation and Travel | $33,269 |
| Office Supplies and Other | $26,937 |
| Rent | $22,000 |
| Conferences and Events | $4,473 |
| IT and Telephone | $4,040 |
| Bank Fees | $3,864 |
| Insurance | $1,608 |
| Total Program Expenses | $2,815,140 |
Chair's Profession / Business Affiliation
Not disclosed
Board Size
8
Paid Staff Size
9
Method(s) Used:
Direct mail appeals, Invitations to fund raising events, Grant proposals, Internet, Planned giving arrangements, Appeals via Social Media (Facebook, etc.)
This organization is tax-exempt under section 501(c)(3) of the Internal Revenue Code. It is eligible to receive contributions deductible as charitable donations for federal income tax purposes.
The following information is based on Drugs For Neglected Diseases Initiative, North America's audited financial statements for the year ended December 31, 2022.
Source of Funds
| Contributions | $3,659,059 |
| Fondations | $190,077 |
| ERC Credit | $59,419 |
| Interest income and other | $23,387 |
| Total Income | $3,931,942 |
Programs: 73% Fundraising: 12% Administrative: 15%
| Total Income | $3,931,942 |
| Total expenses: | $3,853,071 |
| Program expenses | $2,815,140 |
| Fundraising expenses | $477,449 |
| Administrative expenses | $560,482 |
| Other expenses | $0 |
| Income in Excess of Expenses | $78,871 |
| Beginning Net Assets | $847,022 |
| Other Changes In Net Assets | $0 |
| Ending Net Assets | $925,893 |
| Total Liabilities | $229,562 |
| Total Assets | $0 |
An organization may change its practices at any time without notice. A copy of this report has been shared with the organization prior to publication. It is not intended to recommend or deprecate, and is furnished solely to assist you in exercising your own judgment. If the report is about a charity and states the charity meets or does not meet the Standards for Charity Accountability, it reflects the results of an evaluation of information and materials provided voluntarily by the charity. The name Better Business Bureau is a registered service mark of the International Association of Better Business Bureaus.
This report is not to be used for fundraising or promotional purposes.
RELATED CONTENT
-
Meets Standards
-
Standards Not Met
-
Did Not Disclose
-
Review in Progress
-
Unable to Verify
Report completed by:
BBB Foundation of Metropolitan New York